VERTEBRAL AUGMENTATION PROCEDURE (VAP)/
PERCUTANEOUS VERTEBROPLASTY

Guideline Number: MPG345.06  Approval Date: August 12, 2020

Table of Contents

<table>
<thead>
<tr>
<th>POLICY SUMMARY</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>APPLICABLE CODES</td>
<td>1</td>
</tr>
<tr>
<td>PURPOSE</td>
<td>2</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>3</td>
</tr>
<tr>
<td>GUIDELINE HISTORY/REVISION INFORMATION</td>
<td>4</td>
</tr>
<tr>
<td>TERMS AND CONDITIONS</td>
<td>5</td>
</tr>
</tbody>
</table>

POLICY SUMMARY

Overview
Percutaneous Vertebral Augmentation
Percutaneous vertebral augmentation (PVA) is a minimally invasive procedure for the treatment of compression fractures of the vertebral body. The procedure includes a cavity creation which results in fracture reduction along with an attempt to restore vertebral body height and alignment. Using image guidance x-rays, incisions are made and a probe is placed into the vertebral space in the location of the fracture. The collapsed vertebral body is drilled and a device which displaces, removes or compacts the compressed area of the vertebrae is used to create a cavity prior to injection of bone filler (polymethylmethacrylate) (PMMA).

Percutaneous Vertebroplasty
Percutaneous vertebroplasty (PVP) is a therapeutic, interventional neurosurgical and radiological procedure that consists of the percutaneous injection of a biomaterial, methyl methacrylate, into a lesion of a thoracic or lumbar vertebral body. The procedure is utilized for pain relief and bone strengthening of weakened vertebral bodies.

The procedure is performed under fluoroscopic guidance, although some prefer the use of computed tomography (CT) with fluoroscopy for needle positioning and injection assessment. An intraosseous venogram is sometimes performed before cement injection to determine whether the needle is positioned within a direct venous anastomosis to the central or epidural veins, to minimize extravasation into venous structures. Conscious sedation with additional local anesthesia (1% lidocaine) is generally utilized; however, patients who experience difficulties with ventilation or are unable to tolerate prone position during the procedure may require general anesthesia or deep sedation with airway and ventilation support. The methyl methacrylate is injected into the vertebral body until resistance is met or until cement reaches the posterior wall.

Guidelines
PVA (percutaneous vertebroplasty (PVP) or kyphoplasty (PKP)) is covered for Osteoporotic Vertebral Compression Fracture (VCF) in patients with BOTH the following:

- Inclusion criteria (ALL are required):
  - Acute* (< 6 weeks) osteoporotic VCF (T5 – L5) by recent (within 30 days) advanced imaging (bone marrow edema on MRI or bone-scan/SPECT/CT uptake)
  - Symptomatic (ONE):
    - Hospitalized with severe pain (Numeric Rating Scale (NRS) or Visual Analog Scale (VAS) pain score ≥ 8)
    - Non-hospitalized with moderate to severe pain (NRS or VAS ≥5) despite optimal non-surgical management (NSM) (10)** (ONE):
      - Worsening pain
      - Stable to improved pain (but NRS or VAS still ≥5) (with ≥ 2 of the following):
        - Progression of vertebral body height loss

---

*Acute: Time from injury to when patient experiences pain

**NSM: Non-surgical management includes but is not limited to: medication, physical therapy, brace, etc.
• 25% vertebral body height reduction
• Kyphotic deformity
• Severe impact of VCF on daily functioning (Roland Morris Disability Questionnaire (RDQ) >17

  o Multidisciplinary team consensus (2) (ALL are required)
    ▪ Referring physician (e.g., rheumatologist, endocrinologist)
    ▪ Treating physician (i.e., performing the PVA)
    ▪ Radiologist
    ▪ Neurologist

• Exclusion criteria (Can have NONE of the following):
  o Absolute contraindication
    ▪ Current back pain is not primarily due to the identified acute VCF(s).
    ▪ Osteomyelitis, discitis or active systemic infection
    ▪ Pregnancy
    ▪ Greater than three vertebral fractures
  o Relative contraindication
    ▪ Allergy to bone cement or opacification agents
    ▪ Coagulopathy
    ▪ Spinal instability
    ▪ Myelopathy from the fracture
    ▪ Neurologic deficit
    ▪ Neural impingement
    ▪ Fracture retropulsion/canal compromise**

*At least an acute component (e.g., acute on chronic)

**Consider including pedicle periosteal infiltration

Note: See Local Coverage Determination (LCD) References for coverage details. Coverage for Malignant Vertebral Fractures varies by LCD.

APPLICABLE CODES

The following list(s) of codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this guideline does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>22510</td>
<td>Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; cervicothoracic</td>
</tr>
<tr>
<td>22511</td>
<td>Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; lumbosacral</td>
</tr>
<tr>
<td>22512</td>
<td>Percutaneous vertebroplasty (bone biopsy included when performed), 1 vertebral body, unilateral or bilateral injection, inclusive of all imaging guidance; each additional cervicothoracic or lumbosacral vertebral body (List separately in addition to code for primary procedure)</td>
</tr>
<tr>
<td>22513</td>
<td>Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (e.g., kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; thoracic</td>
</tr>
<tr>
<td>22514</td>
<td>Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (e.g., kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; lumbar</td>
</tr>
</tbody>
</table>
### CPT Code | Description
--- | ---
22515 | Percutaneous vertebral augmentation, including cavity creation (fracture reduction and bone biopsy included when performed) using mechanical device (e.g., kyphoplasty), 1 vertebral body, unilateral or bilateral cannulation, inclusive of all imaging guidance; each additional thoracic or lumbar vertebral body (List separately in addition to code for primary procedure)
22899 | Unlisted procedure, spine

*CPT® is a registered trademark of the American Medical Association*

### PURPOSE

The Medicare Advantage Policy Guideline documents are generally used to support UnitedHealthcare Medicare Advantage claims processing activities and facilitate providers’ submission of accurate claims for the specified services. The document can be used as a guide to help determine applicable:

- Medicare coding or billing requirements, and/or
- Medical necessity coverage guidelines; including documentation requirements

UnitedHealthcare follows Medicare guidelines such as LCDs, NCDs, and other Medicare manuals for the purposes of determining coverage. It is expected providers retain or have access to appropriate documentation when requested to support coverage. Please utilize the links in the **REFERENCES** section below to view the Medicare source materials used to develop this resource document. This document is not a replacement for the Medicare source materials that outline Medicare coverage requirements. Where there is a conflict between this document and Medicare source materials, the Medicare source materials will apply.

### REFERENCES

**CMS Local Coverage Determinations (LCDs) and Articles**

<table>
<thead>
<tr>
<th>LCD</th>
<th>Article</th>
<th>Contractor</th>
<th>Medicare Part A</th>
<th>Medicare Part B</th>
</tr>
</thead>
<tbody>
<tr>
<td>L33569 (Percutaneous Vertebral Augmentation (PVA) for Osteoporotic Vertebral Compression Fracture (VCF))</td>
<td>A56178 (Billing and Coding: Percutaneous Vertebral Augmentation (PVA) for Osteoporotic Vertebral Compression Fracture (VCF))</td>
<td>NGS</td>
<td>CT, IL, MA, ME, MN, NH, NY, RI, VT, WI</td>
<td>CT, IL, MA, ME, MN, NH, NY, RI, VT, WI</td>
</tr>
<tr>
<td>L38201 (Percutaneous Vertebral Augmentation (PVA) for Osteoporotic Vertebral Compression Fracture (VCF))</td>
<td>A57282 (Billing and Coding: Percutaneous Vertebral Augmentation (PVA) for Osteoporotic Vertebral Compression Fracture (VCF))</td>
<td>CGS</td>
<td>KY, OH</td>
<td>KY, OH</td>
</tr>
<tr>
<td>L34048 (Vertebroplasty and Vertebral Augmentation - Percutaneous) Retired 11/17/2019 (See L38201)</td>
<td>A56801 (Billing and Coding: Vertebroplasty and Vertebral Augmentation (Percutaneous))</td>
<td>Retired 11/17/2019 (See A57282)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>L34106 (Percutaneous Vertebral Augmentation (PVA) for Osteoporotic Vertebral Compression Fracture (VCF))</td>
<td>A56573 (Billing and Coding: Percutaneous Vertebral Augmentation (PVA) for Osteoporotic Vertebral Compression Fracture (VCF))</td>
<td>Noridian</td>
<td>AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY</td>
<td>AK, AZ, ID, MT, ND, OR, SD, UT, WA, WY</td>
</tr>
</tbody>
</table>

Vertebral Augmentation Procedure (VAP)/Percutaneous Vertebroplasty
UnitedHealthcare Medicare Advantage Policy Guideline

_Proprietary Information of UnitedHealthcare. Copyright 2020 United HealthCare Services, Inc._

Page 3 of 6
Approved 08/12/2020
Vertebral Augmentation Procedure (VAP)/Percutaneous Vertebroplasty
UnitedHealthcare Medicare Advantage Policy Guideline

Proprietary Information of UnitedHealthcare. Copyright 2020 United HealthCare Services, Inc.

Revisions to this summary document do not in any way modify the requirement that services be provided and documented in accordance with the Medicare guidelines in effect on the date of service in question.

<table>
<thead>
<tr>
<th>Date</th>
<th>Policy Summary</th>
<th>Action/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>08/12/2020</td>
<td><strong>Policy Summary</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Overview</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Removed language indicating the <strong>percutaneous vertebroplasty (PVP)</strong> procedure usually lasts from 1 to 2 hours, unless cement is injected into two or more vertebral bodies</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Guidelines</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Revised language to indicate <strong>percutaneous vertebral augmentation (PVA)</strong> [percutaneous vertebroplasty (PVP) or kyphoplasty (PKP)] is covered for <strong>osteooporotic vertebral compression fracture (VCF)</strong> in patients with <strong>both</strong> the following:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>o Inclusion criteria (all are required):</td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ Acute (at least an acute component [e.g., acute on chronic]) (&lt; 6 weeks) osteoporotic VCF (T5–L5) by recent (within 30 days) advanced imaging (bone marrow edema on MRI or bone-scan/SPECT/CT uptake)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>▪ Symptomatic (one of the following):</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Hospitalized with severe pain (Numeric Rating Scale [NRS] or Visual Analog Scale [VAS] pain score ≥ 8)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Non-hospitalized with moderate to severe pain (NRS or VAS ≥ 5)</td>
<td></td>
</tr>
</tbody>
</table>
### Multidisciplinary team consensus (all are required):
- Referring physician (e.g., rheumatologist, endocrinologist)
- Treating physician (i.e., performing the PVA)
- Radiologist
- Neurologist

- Exclusion criteria (can have none of the following):
  - Absolute contraindication
    - Current back pain is not primarily due to the identified acute VCF(s).
    - Osteomyelitis, discitis or active systemic infection
    - Pregnancy
    - Greater than three vertebral fractures
  - Relative contraindication
    - Allergy to bone cement or opacification agents
    - Coagulopathy
    - Spinal instability
    - Myelopathy from the fracture
    - Neurologic deficit
    - Neural impingement
    - Fracture retropulsion/canal compromise

- Updated notation to indicate coverage for malignant vertebral fractures varies by LCD

### Applicable Codes
- Removed CPT codes 0200T and 0201T

### Supporting Information
- Updated References section to reflect the most current information
- Archived previous policy version MPG345.05

## TERMS AND CONDITIONS

The Medicare Advantage Policy Guidelines are applicable to UnitedHealthcare Medicare Advantage Plans offered by UnitedHealthcare and its affiliates.

These Policy Guidelines are provided for informational purposes, and do not constitute medical advice. Treating physicians and healthcare providers are solely responsible for determining what care to provide to their patients. Members should always consult their physician before making any decisions about medical care.

Benefit coverage for health services is determined by the member specific benefit plan document* and applicable laws that may require coverage for a specific service. The member specific benefit plan document identifies which services are covered, which are excluded, and which are subject to limitations. In the event of a conflict, the member specific benefit plan document supersedes the Medicare Advantage Policy Guidelines.

Medicare Advantage Policy Guidelines are developed as needed, are regularly reviewed and updated, and are subject to change. They represent a portion of the resources used to support UnitedHealthcare coverage decision making. UnitedHealthcare may modify these Policy Guidelines at any time by publishing a new version of the policy on this website. Medicare source materials used to develop these guidelines include, but are not limited to, CMS National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), Medicare Benefit Policy Manual, Medicare Claims Processing Manual, Medicare Program Integrity Manual, Medicare Managed Care Manual, etc. The information presented in the Medicare Advantage Policy Guidelines is believed to be accurate and current as of the date of publication, and is provided on an "AS IS" basis. Where there is a conflict between this document and Medicare source materials, the Medicare source materials will apply.

---

You are responsible for submission of accurate claims. Medicare Advantage Policy Guidelines are intended to ensure that coverage decisions are made accurately based on the code or codes that correctly describe the health care services provided. UnitedHealthcare Medicare Advantage Policy Guidelines use Current Procedural Terminology (CPT®), Centers for Medicare and Medicaid Services (CMS), or other coding guidelines. References to CPT® or other sources are for definitional purposes only and do not imply any right to reimbursement or guarantee claims payment.

Medicare Advantage Policy Guidelines are the property of UnitedHealthcare. Unauthorized copying, use and distribution of this information are strictly prohibited.

*For more information on a specific member’s benefit coverage, please call the customer service number on the back of the member ID card or refer to the Administrative Guide.